Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
BioNTech, Jefferies and ADR
BioNTech SE ADR falls Wednesday, underperforms market
The BioNTech SE ADR BNTX slipped 7.29% to $115.62 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,618.26 and Dow Jones Industrial Average DJIA falling 0.
UBS Keeps Their Hold Rating on BioNTech SE (BNTX)
UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The
Jefferies Upgrades BioNTech SE - Depositary Receipt () (BNTX)
Fintel reports that on September 17, 2024, Jefferies upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) from Hold to Buy. Analyst Price Forecast Suggests 8.06% Downside As of August 25,
BioNTech SE ADR rises Tuesday, outperforms market
The BioNTech SE ADR BNTX rallied 1.00% to $124.71 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.03% to 5,634.58 and the Dow Jones Industrial Average DJIA falling 0.04% to 41,606.18.
Hosted on MSN
1d
How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit ...
1d
on MSN
BioNTech raised to buy at Jefferies on new cancer drug
BioNTech (NASDAQ:BNTX) shares traded higher on Tuesday after Jefferies upgraded the German COVID-19 vaccine maker to Buy from ...
1d
Decoding BioNTech's Options Activity: What's the Big Picture?
Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...
1d
BioNTech SE: A Strong Buy on BNT327’s Promising Cancer Treatment Prospects and Financial Fortitude
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...
7d
BioNTech's Low Valuation, Many Shots On Goal Make It A Buy
BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.
5d
Forecasting The Future: 8 Analyst Projections For BioNTech
BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...
Zacks.com on MSN
5d
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
2d
Monday's Moving Stocks: RH, BioNTech, and More
Inflation generally hurts disposable income. This discourages consumers from buying high-priced items like furnishings and ...
2minutemedicine.com
15d
BioNTech’s mRNA Cancer Candidate Packs A Punch With Regeneron’s Cemiplimab In Phase 2 Melanoma Trial
Treatment with BNT111 + cemiplimab showed a statistically significant overall response in patients with inoperable or ...
1d
on MSN
Moderna Stock Jumps on Canadian Government's Approval of Updated COVID-19 Vaccine
Key Takeaways Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Dow Jones Industrial Average
Trade
BNT327
Jefferies Group
Feedback